1. ホーム
  2. 一覧
論文 特許

論文 - 一覧

  • 46 Hits
  • 検索条件 : 絞込み (MeSH = Carcinoma, Non-Small-Cell Lung / drug therapy*)
生物種 リソース名 タイトル
ヒト・動物細胞 EBC-1(RCB1965) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.
ヒト・動物細胞 II-18(RCB2093) , PC-14(RCB0446) , RERF-LC-KJ(RCB1313) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
ヒト・動物細胞 LC-2/ad(RCB0440) HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
ヒト・動物細胞 Ba/F3(RCB0805) Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
ヒト・動物細胞 PC-9(RCB4455) A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
ヒト・動物細胞 A549(RCB0098) Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
ヒト・動物細胞 PC-9(RCB4455) Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
ヒト・動物細胞 PC-9(RCB4455) Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
ヒト・動物細胞 PC-9(RCB4455) Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
ヒト・動物細胞 PC-9(RCB4455) Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
ヒト・動物細胞 A549(RCB0098) Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
ヒト・動物細胞 KP4(RCB1005) Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
ヒト・動物細胞 PC-9(RCB4455) Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
ヒト・動物細胞 PC-9(RCB4455) ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
ヒト・動物細胞 LK-2(RCB1970) , RERF-LC-AI(RCB0444) , EBC-1(RCB1965) , LC-1/sq-SF(RCB0438) Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
ヒト・動物細胞 A549(RCB0098) Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells.
ヒト・動物細胞 PC-9(RCB4455) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
ヒト・動物細胞 KP4(RCB1005) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
ヒト・動物細胞 LC-2/ad(RCB0440) Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
ヒト・動物細胞 A549(RCB0098) , WI-38(RCB0702) p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.